P atients with heart failure and preserved ejection fraction (HFpEF) are more frequently women, usually elderly with a history of hypertension and commonly have multiple comorbidities including obesity, anemia, diabetes mellitus, and renal dysfunction. Each of these comorbidities may influence ventricular and vascular structure and function, provoking debate as to whether HFpEF is a distinct disease requiring specific therapy or simply an amalgamation of age-related comorbidities. [1] [2] [3] We hypothesized that HFpEF, as it presents in the community, is associated with unique alterations in ventricular-vascular properties after accounting for the confounding influences of age, sex, body size, and comorbidities. Accordingly, we compared ventricular-vascular properties in a community-based cohort of HFpEF patients and control populations without heart failure (HF). To account for the effects of age, sex, and hypertension, we compared HFpEF patients with carefully age-and sex-matched normotensive (CON) and hypertensive (HTN) comparator populations from the same community. To account for body size differences, ventricular-vascular properties were scaled to allometric coefficients generated in an age-appropriate, disease-free, normal body size cohort. To account for the effects of comorbidities, comparison between HFpEF and control populations adjusted for comorbidities and the impact of comorbidities on ventricular-vascular properties and survival among HFpEF patients was defined.
Methods
The study was approved by Mayo Clinic institutional review board and all subjects gave prospective consent or consent for use of medical records for research.
Study Subjects
Consecutive adult patients with HF (Framingham criteria) were prospectively enrolled between September 2003 and August 2009 by real-time interrogation of electronic medical records using natural language processing techniques as previously described. 4 This cohort is derived from an ongoing prospective study and includes subjects included in earlier analyses of smaller subsets addressing other hypotheses. Subjects with significant left-sided valve disease, infiltrative, inflammatory or hypertrophic cardiomyopathy, congenital heart disease, pericardial disease, ejection fraction (EF)<50% or without assessment of vascular structure (ascending aortic diameter) were excluded. Vital status was determined from Rochester Epidemiology Project procedures as previously described. 5 To identify unique age-and sex-matched CON (no HTN, diabetes mellitus, vascular or valve disease or HF) and HTN (but no HF) comparator groups, we used stratified random sampling of Olmsted County residents in the Mayo Clinic Echocardiographic Laboratory database (February 1998-June 2010) and manual medical record review (Selma F. Mohammed, MBBS) with matching in a 1:2:2 ratio of CON: HTN: HFpEF.
Physician's diagnoses with documentation of clinical features, supportive laboratory or imaging data, and medication use were used to define clinical characteristics (see Methods in the online-only Data Supplement) including medication use at the time of the index echocardiogram. Body surface area was calculated by the Gehan method (BSA=0.0235×height (cm) 0.42246 ×weight(kg) 0.51456 ) and body mass index as weight/height 2 (kg/m 2 ).
Doppler Echocardiography
Echocardiograms were performed by registered cardiac diagnostic sonographers and interpreted by echocardiologists.
Cardiac Structure and Function
Left ventricle (LV) and atrial geometry were measured with 2D or M-mode echocardiography and used to calculate EF, LV mass, relative wall thickness, left atrial volume (area-length method), stroke volume (SV), and pulmonary artery systolic pressure (PASP) according to American Society of Echocardiography conventions. 5, 6 LV end-diastolic volume (EDV) was calculated using SV and EF to avoid geometric assumptions (EDV=SV/EF). 4, 7 Cardiac power output (CPO) was computed (cardiac output [CO]×mean arterial pressure [MAP]×2.22×10 -3 ) in watts. 8 The early diastolic septal annular tissue velocity (e'), transmitral flow velocity (E), and deceleration time were used to quantify relaxation, filling pressure (E/e'), and operant diastolic stiffness. To estimate LV operating compliance (EDV at a given end diastolic pressure), natural log of EDV was compared between groups adjusting for age, sex, body size (natural log of height and natural log of weight), comorbidities, and quartiles of E/e' (see Methods in the online-only Data Supplement).
Vascular Structure and Function
Aortic diameter (D) was used to calculate aortic area (πD 2 /4). Brachial pulse pressure (PP; systolic-diastolic blood pressure), (MAP, diastolic blood pressure+0.4128×PP), 8 end systolic pressure (ESP; 0.9×brachial systolic blood pressure), 9 effective arterial elastance (Ea; ESP/ SV), 9 total systemic arterial compliance (SAC; SV/PP), and systemic vascular resistance (SVR;[MAP/CO]×80) were calculated as previously described. 4 All comparisons of Ea and SAC between groups were adjusted for heart rate and MAP, respectively.
Allometric Scaling
Because the relationship between body size and physiologic parameters is often complex and nonlinear, simple ratiometric scaling to height or BSA may yield erroneous conclusions. 8, [10] [11] [12] We assembled a disease-free, community-based cohort with a normal body size (<25 kg/m 2 ; n=345; characteristics in the online-only Data Supplement  Table I ) to derive age and sex appropriate allometric scaling coefficients (see Methods in the online-only Data Supplement). Allometric coefficients were obtained by regressing the natural log of the ventricular-vascular properties on log of height or BSA after adjustment for age and sex. This log-log method effectively results in a multiplicative model 13 that has the same functional form as the standard allometric equations and yields nearly identical results as nonlinear regression. 12 Whereas sex-body size interaction terms were not significant, the age-body size interaction terms were significant for most parameters. Thus, scaling coefficients were derived in a subset (age >median) of the normal cohort with an age distribution similar to the HFpEF and comparator populations (see Methods and Tables I and II in the online-only Data Supplement). This age-appropriate, normal body size cohort was also used to derive upper normal values (mean+2SD) for allometrically scaled LV mass measurements.
Sensitivity Analyses
To further evaluate differences in ventricular-vascular properties adjusting for body size, a sensitivity analysis was performed using multivariable least squares linear regression to compare log-transformed ventricular-vascular properties between groups (dummy variables) adjusting for log-transformed height and weight as well as age, sex, and comorbidities rather than using the allometric scaling indices derived in the normal populations.
Laboratory Data
Glomerular filtration rate was estimated using the modification of diet in renal disease formula.
Missingness
The missingness rate for all variables with <100% availability is shown in the online-only Data Supplement Table III .
Statistical Analysis
Data are presented as mean±SD or % frequency. For continuous variables, comparisons across groups were performed by 1-way ANOVA followed by Dunnet's test for group comparisons to HFpEF. For categorical variables, comparisons across and between groups were performed by the χ 2 test. Multivariable least squares linear regression was used to test multiple covariates where groups were entered as dummy variables appropriately constructed for the comparison of interest.
Comparisons of ventricular-vascular properties between HFpEF patients with or without an individual comorbidity (anemia, diabetes mellitus, or renal dysfunction) was performed in log-log models where the log-transformed variables were compared between groups adjusting for natural log of height, natural log of weight, and other concomitant comorbidities. Comparisons of ventricular-vascular properties between HFpEF patients with or without obesity was similarly performed adjusting for natural log of height and other concomitant comorbidities. For parameters not related to body size, comparisons adjusted for other comorbidities. The adjusted geometric means within groups and the P value for the group effect are presented.
Survival up to 5 years after HF diagnosis was assessed. The Kaplan-Meier method tested for differences in survival between groups by the log-rank test. Cox proportional-hazards regression was used to adjust for the effect of differences in baseline characteristics on survival.
All analyses were 2 tailed, and a P<0.05 was considered statistically significant. Analysis was performed using the JMP ® analysis software.
Results

Clinical Characteristics
HFpEF subjects were elderly and predominately women with a high prevalence of obesity, anemia, diabetes mellitus, renal dysfunction, cardiovascular conditions, and medication use November 2012 (Table 1 ). Systolic and mean blood pressures were higher in HFpEF than CON but lower in HFpEF than HTN, whereas PP was higher in HFpEF than CON but similar to HTN.
Differences across groups were similar in men and women (in the online-only Data Supplement Table IV ) although men with HFpEF were younger and had more vascular disease than women with HFpEF.
Cardiac Structure
HFpEF patients had higher height-or BSA-scaled LV mass than CON or HTN ( Table 2 ). In the sensitivity analysis, natural log of LV mass was greater in HFpEF than CON or HTN ( Table 3 ). HFpEF patients had more abnormal LV geometry ( Figure 1 ) whether the presence of LV hypertrophy was ascertained using the allometrically scaled or published (sex-specific LV mass/BSA) hypertrophy criteria.
Height-or BSA-scaled EDV was not different in HFpEF than CON but tended to be (height-scaled) or was (BSA-scaled) smaller in HFpEF than HTN ( Table 2 ). In the sensitivity analysis, natural log of EDV was similar in HFpEF and CON but smaller in HFpEF than HTN (Table 3) .
HFpEF patients had larger height-or BSA-scaled left atrial volume than CON or HTN ( Table 2) . The difference in left atrial volume between HFpEF and CON (P<0.001) or HTN (P<0.001) persisted after also adjusting for the presence of atrial fibrillation. Similarly, in the sensitivity analysis, natural log of left atrial volume was greater in HFpEF than CON or HTN ( Table 3 ) and when also adjusting for atrial fibrillation (P<0.001).
LV Systolic Function
EF was slightly but significantly lower in HFpEF than CON or HTN ( Table 2 ). The lower EF in HFpEF compared with CON (P=0.002) or HTN (P<0.001) persisted after also adjusting for the presence of coronary disease.
Height-scaled SV was similar in HFpEF and CON but BSA-scaled SV was lower in HFpEF than CON ( Table 2) . Height-or BSA-scaled SV was lower in HFpEF than HTN. In sensitivity analysis, natural log of SV was smaller in HFpEF than CON or HTN (Table 3 ). Differences in CO were similar to SV (and significant) across groups(data not shown).
Height-or BSA-scaled CPO in HFpEF was similar to CON but lower than HTN ( Table 2 ). In sensitivity analysis, natural log of CPO in HFpEF was similar to CON but <HTN (Table 3 ).
LV Diastolic Function
E/e', PASP, and deceleration time were more abnormal in HFpEF than CON or HTN ( Table 2) . Adjusting for age, sex, natural log of height, natural log of weight, comorbidities, and E/e', natural log of EDV was smaller in HFpEF than HTN (Table 4 ) consistent with lower diastolic operating compliance. Given the limited range of E/e' in CON, this analysis was restricted to HFpEF and HTN subjects.
Vascular Structure and Function
Aortic area was larger in HFpEF than CON but similar to HTN ( Table 5 ). In sensitivity analysis, natural log of aortic area was similar in HFpEF, CON, and HTN (Table 3) .
Height-or BSA-scaled Ea was higher in HFpEF than CON and tended to be higher in HFpEF than HTN (Table 5 ). In sensitivity analysis, natural log of Ea was higher in HFpEF than CON and tended to be higher than HTN (Table 3) .
Height-or BSA-scaled SVR was higher in HFpEF than CON but similar in HFpEF and HTN (Table 5 ). In sensitivity analysis, natural log of SVR was higher in HFpEF than CON but similar in HFpEF and HTN (Table 3) .
Height-or BSA-scaled SAC was lower in HFpEF than CON and tended to be (Height-scaled) or was (BSA-scaled) lower in HFpEF than HTN (Table 5 ). In sensitivity analysis, natural log of SAC was lower in HFpEF than CON or HTN (Table 3 ).
Comorbidities and Ventricular and Vascular Structure and Function in HFpEF
Obesity
Obesity was present in 42% of HFpEF patients (Table 6 ). Obese HFpEF patients were younger, more likely diabetic and had higher hemoglobin and PP than nonobese HFpEF patients. Obese patients had higher LV mass, EDV, and atrial volume with higher relative wall thickness suggesting concentric remodeling. Obese HFpEF patients tended to have higher EF and had higher SV, CO, and CPO than nonobese HFpEF patients but diastolic function indices were similar. Whereas LV operating compliance (Table 4 ) increased with increasing weight and height, there was no leftward shift of this relationship in obese patients to suggest worse diastolic function.
Aortic area and SAC were larger, Ea was and SVR tended to be lower in obese HFpEF patients suggesting that the higher PP in obese patients reflects the higher SV rather than greater arterial stiffness. Mean and median follow-up among HFpEF survivors was 4.2±1.1 and 4.9 years, respectively. Obesity was associated with better outcome adjusting for age, sex, and other concomitant comorbidities (Figure 2A and 2E). The relationship between obesity and outcomes did not appear U-shaped (in the online-only Data Supplement Figure) . Figure 2B and 2E ).
Diabetes Mellitus
Diabetes mellitus was present in 35% of HFpEF patients ( Table 6 ). Diabetic HFpEF patients were younger, more obese and had worse renal function, and higher PP than nondiabetics. Adjusting for age, sex, height, weight, and other comorbidities, diabetic HFpEF patients tended to have higher LV mass but had similar EDV and systolic function to nondiabetics. Diabetics had higher E/e' but other diastolic parameters, including operating compliance (Table 4) were similar. Diabetic patients had smaller aortas and lower SAC than nondiabetics. Whereas Ea and SVR were similar, PP was higher in diabetics before (P<0.001) and after adjustment for age, sex and other comorbidities ( Table 6 ). The higher PP was also apparent after also adjusting for MAP and MAP 2 (P<0.001) and given the similar SV, these parameters suggest stiffer vasculature in diabetic HFpEF patients. 14 Figure 2C and 2E) . Compared with nondiabetics, diabetic HFpEF patients were more frequently treated with beta blockers (58% nondiabetic versus 72% diabetic), angiotensin antagonists (40% nondiabetic versus 73% diabetic) and statins (37% nondiabetic versus 67% diabetic) (P<0.01 for all).
Diabetes
Renal Dysfunction
HFpEF patients with renal dysfunction were older, more often women, and had lower hemoglobin and pulse pressures than patients without renal dysfunction (Table 6) . Adjusting for age, sex, height, weight, and other comorbidities, EF and PASP were higher in renal dysfunction patients but all other ventricular-vascular properties were similar to those with better renal function (Tables 5 and 6 ). Renal dysfunction was associated with poorer outcome adjusting for age and sex, and other concomitant comorbidities ( Figure 2D and 2E ).
Discussion
In this large, prospectively identified, rigorously characterized HFpEF cohort, we found that compared with age-and sex-matched normotensive and hypertensive controls, HFpEF patients consistently displayed abnormalities in ventricularvascular properties above and beyond that explainable by comorbidity burden and body size. Among HFpEF patients, comorbidities were associated with unique clinical, structural, functional, and prognostic profiles. Obese patients were younger, and whereas they displayed greater concentric remodeling, their LV systolic and vascular function and outcomes were better than nonobese HFpEF patients. Anemic patients were older, displayed ventricular and vascular characteristics consistent with a high(er) output state, and had worse outcomes than nonanemic HFpEF patients. Diabetic patients were younger and heavier and had higher filling pressures and stiffer vasculature, yet they were aggressively treated and their outcomes were similar to nondiabetics. Patients with renal dysfunction were older and despite a lack of unique structural or functional features, they had worse outcomes than patients with better renal function. Although these data confirm that comorbidities influence ventricular-vascular properties and outcomes among HFpEF patients, they underscore that fundamental disease-specific changes in cardiovascular function underlie this disorder and support the search for specific therapies. 
Comorbidities and Ventricular and Vascular Structure and Function in HFpEF
We have previously characterized cardiovascular structure and function in a smaller cohort of HFpEF patients. 4, 7, 15 The current analysis differs in several important ways. The prospectively enrolled HFpEF cohort is larger and the comparator groups are matched for age and sex, whereas comparator populations in the previous studies were on average 10 (HTN) to 20 (CON) years younger than the HFpEF population. The current data utilize more appropriate analyses to account for differences in body size, vascular structure is assessed, analyses are adjusted in the primary and sensitivity analyses for comorbidities, and potential differences among HFpEF patients according to the presence of key comorbidities are evaluated. The current focus on the association between comorbidities and differences in ventricular-vascular properties between HFpEF and control populations or within HFpEF patients is important because comorbidities have significant effects on cardiovascular structure and function in non-HF populations and in animal models. Obesity has been linked to pathologic LVH, atrial enlargement, systolic and diastolic LV dysfunction, endothelial dysfunction, vasoconstriction and increased vascular stiffness. 11, 16 Chronic severe anemia decreases SVR and leads to volume expansion, eccentric remodeling, and LV systolic and diastolic dysfunction. 17, 18 Diabetes mellitus has been linked to LVH, systolic and diastolic LV dysfunction, endothelial dysfunction, and increased vascular stiffness. 19, 20 Intrinsic renal disease is associated with apoptosis, fibrosis, hypertrophy, and LV dysfunction. 21, 22 Thus, the potential for comorbidities to account for the alterations in LV structure and function observed in HFpEF patients is real.
Here, with strict attention to matching for age, sex, and hypertension, appropriate analyses for body size-related differences and adjustment for comorbidities, we demonstrate that HFpEF is independently associated with more severe alterations in ventricular-vascular properties than observed in healthy or hypertensive controls. Specifically, compared with healthy controls, HFpEF patients had more cardiac remodeling (concentric LVH and larger atria), systolic (lower EF) and diastolic (higher E/e' and PASP and lower e' and deceleration time) dysfunction, and more abnormal vascular function (higher Ea and SVR and lower SAC). Compared with hypertensive controls, HFpEF patients had more cardiac remodeling (concentric LVH and larger atria), systolic (lower EF, CO, and CPO) and diastolic (higher E/e' and PASP and lower e', deceleration time and operating compliance) dysfunction whereas vascular function was not consistently and only subtly more impaired in HFpEF than HTN.
Notably, adjusting for body size differences (Tables 3 and  5 ) aortic size was similar across the CON, HTN, and HFpEF groups. These data suggest that intrinsic stiffening of the aorta, rather than further degenerative expansion, contributes to vascular stiffening in HFpEF versus CON and HTN as previously suggested. 23 It may be that HFpEF represents a unique synergistic interaction between the effects of aging, hypertension, and comorbidities, particularly cardiovascular comorbidities, to promote ventricular and vascular remodeling and dysfunction but in the absence of a large myocardial infarction leading to reduced EF. 24 If so, measures to ensure healthy aging, treatment of risk factors, and prevention of other comorbidities would likely prevent or delay the onset of HFpEF. The factors that mediate progression from HTN to HFpEF are not yet clear. Quantification of the severity, duration, and control of hypertension over time is difficult and thus we are unable to determine whether a greater lifetime burden of arterial HTN mediates the more severe remodeling, ventricular dysfunction and vascular dysfunction associated with HFpEF compared with age/sex-matched HTN controls. Because essential HTN is a polygenic disease, there may be greater susceptibility to HFpEF in certain genetic subtypes or unique interactions with behavioral modulators.
Impact of Comorbidities Among HFpEF Patients
It is notable that male, obese and diabetic HFpEF patients present at a younger age, underscoring the variability in the syndrome beyond the stereotypical profile of frail, elderly, hypertensive females. This may suggest that the interaction of aging and HTN is sufficient to cause HFpEF in some patients, but that comorbidities may play a role in accelerating progression to HFpEF in others.
Obese HFpEF patients had higher LV mass, EDV and atrial size, better preserved systolic performance and more preserved vascular function compared with nonobese HFpEF patients. Because most of these parameters are related to body size, and particularly weight, determining whether these changes represent a physiologic adaptation to higher metabolic demands or pathologic remodeling is difficult. It is important to note that in non-HF cohorts, body size-independent vascular parameters are more abnormal in obese subjects and increases in height-scaled LV mass are associated with poorer outcomes in general population-based studies. 11, 12 However, here, compared with nonobese HFpEF patients, obese HFpEF patients had better survival as has been noted in both HFpEF and HF reduced ejection fraction. [25] [26] [27] [28] This obesity paradox has been ascribed to diagnosis bias (misdiagnosis of HF in obese patients), lead time bias (earlier symptom onset attributable to additional metabolic demands of obesity), improved nutritional status or an anti-inflammatory effect of obesity in HF. [25] [26] [27] [28] The characterization of ventricular-vascular parameters in obese and nonobese HFpEF patients in the current study is unique and the better preserved systolic and vascular function may provide insight into the better outcomes observed in obese HFpEF patients. In this community study, the U-shaped relationship between obesity and mortality reported in a large clinical trial HFpEF cohort 28 after adjustment for a large number of covariates was not observed, but our data set and sample size may limit the power to detect such a relationship.
Consistent with studies of severe anemia in animal models and humans without HF, 17, 29, 30 the relatively mild anemia in HFpEF patients was associated with increased LV size and operating compliance, a high(er) output state and lower SVR and Ea, suggesting that anemia uniquely influences ventricular-vascular properties in HFpEF. Whether the well described association between anemia and mortality in HFpEF and HF reduced ejection fraction 31 reflects the additional load and reduced oxygen carrying capacity related to anemia or the effects of the factors causing anemia etiology (iron deficiency, inflammation, hypervolemia) is not clear. 32 Of note, a recent study demonstrated improved functional and structural indices in HFpEF with carefully titrated erythropoieitin treatment. 33 It is of interest that LV dilatation; higher CO, and reduced arterial load Ea were seen in both anemic and obese compared with nonanemic/nonobese HFpEF patients but with divergent associations with outcome. This may suggest relatively more physiologic load in obesity versus pathophysiologic load in anemia in HFpEF but such interpretations are speculative.
Diabetic HFpEF patients had higher filling pressures and evidence of greater arterial stiffness, consistent with invasive studies suggesting increased chamber and myocyte stiffness in HFpEF with diabetes mellitus 34 and animal and human studies demonstrating vascular dysfunction in diabetic, non-HF subjects. 19 The lack of association of diabetes mellitus with poorer outcomes is surprising given that diabetes mellitus was associated with worse outcomes in observational studies and clinical trials including HFpEF patients. [35] [36] [37] [38] [39] [40] However, variable strength of the association of diabetes mellitus with outcomes and variable associations of diabetes mellitus with outcomes according to HF age/etiology/comorbid conditions/ treatment exist in the published studies. The older age of this HFpEF cohort, the more aggressive treatment of diabetic HFpEF patients, the unquantified duration/severity/type of diabetes mellitus in the current study, the community setting, and the high prevalence of obesity in diabetic subjects may have influenced our findings. Potentially, the lack of significant association of diabetes mellitus with worse outcomes relates to the presence of undiagnosed diabetes mellitus/glucose intolerance/metabolic syndrome in the (still overweight) nondiabetic HFpEF group.
HFpEF patients with renal dysfunction were older, had higher systolic, pulse and PASP, and higher EF but did not otherwise differ strikingly from those with better preserved renal function. The strong association of renal dysfunction, age, and diabetes mellitus may confound adjustment and obscure structural and functional changes specific to renal dysfunction. Renal function is dynamic in HF patients and a single point assessment may not reflect the chronic state. None the less, renal dysfunction was associated with worse outcomes in HFpEF as previously described. 41 
Limitations
Ventricular and vascular function indices were estimated from brachial blood pressure and echocardiographic measurements. All measurements were resting and this may limit the identification of important differences in ventricular or vascular reserve function among groups. 42 Cause-specific mortality data were unavailable. Compared with clinical trial populations, all-cause mortality and rehospitalizations in observational studies such as this one are higher than that observed in clinical trial cohorts. However, the severity of HF relative to comorbidity severity may be less in observational studies. Some ventricular-vascular properties may be best scaled to lean body mass but neither lean body mass nor measures of body fat distribution were available.
Conclusion
Although HFpEF occurs in elderly patients with multiple comorbidities, perturbations in cardiovascular structure and function in HFpEF are greater than can be attributed to comorbidities alone, and the search for specific therapies for the more advanced ventricular and vascular dysfunction present in HFpEF should continue. However, among HFpEF patients, comorbidities are associated with important differences in the clinical profile and ventricular-vascular properties which provide insight into their impact on the natural history of HFpEF.
